Integer (ITGR) Expected to Announce Quarterly Earnings on Thursday

Integer (NYSE:ITGR) is projected to announce its Q1 2025 earnings results before the market opens on Thursday, April 24th. Analysts expect Integer to post earnings of $1.28 per share and revenue of $428.51 million for the quarter. Integer has set its FY 2025 guidance at 5.840-6.200 EPS.

Integer (NYSE:ITGR) last issued its earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.46 by ($0.03). Integer had a return on equity of 11.65% and a net margin of 6.92%. The business had revenue of $449.50 million for the quarter, compared to the consensus estimate of $446.28 million. On average, analysts expect Integer to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Integer Price Performance

NYSE ITGR opened at $115.69 on Tuesday. The company has a market cap of $4.04 billion, a PE ratio of 34.43, a P/E/G ratio of 1.72 and a beta of 1.09. Integer has a 52-week low of $104.93 and a 52-week high of $146.36. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.09 and a current ratio of 2.95. The firm’s 50 day moving average price is $121.14 and its 200-day moving average price is $130.50.

Analyst Ratings Changes

A number of brokerages recently weighed in on ITGR. Truist Financial dropped their price objective on Integer from $163.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday, April 11th. Benchmark boosted their price objective on shares of Integer from $140.00 to $150.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Oppenheimer lowered shares of Integer from an “outperform” rating to a “market perform” rating in a report on Friday, February 21st. Raymond James initiated coverage on Integer in a report on Friday, March 28th. They set an “outperform” rating and a $145.00 price objective for the company. Finally, KeyCorp reduced their target price on Integer from $154.00 to $145.00 and set an “overweight” rating on the stock in a research report on Monday. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $145.00.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.